ProCE Banner Activity

MM24: Updated Data and Guidelines on COVID-19 Treatments

Multimedia
In this presentation, Professor Sharon Lewin discusses the FDA approval of remdesivir and the data from the ACTT-1 and WHO SOLIDARITY trials.

Released: October 30, 2020

Expiration: October 29, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS

Director, Doherty Institute
Melbourne Laureate Professor
Director, Cumming Global Centre for Pandemic Therapeutics
Head, Department of Infectious Diseases
The University of Melbourne
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.